Incyte's Oral Skin Drug Povorcitinib Delivers Strong Long-Term Symptom Relief in Late-Stage Trials
INCY sits 69% above its 52-week low of $53.56.
Summary
Incyte announced highly positive long-term data from two late-stage trials for its experimental oral skin disease drug, povorcitinib, in patients with moderate to severe hidradenitis suppurativa (HS). The data, presented at a medical meeting, showed up to 71.4% of patients achieved at least a 50% reduction in abscesses and inflamed skin bumps after 54 weeks, with some achieving complete lesion clearance. This is new, material information for Incyte, as povorcitinib, a JAK1 inhibitor, is already under review by the FDA and EMA. The strong efficacy and oral formulation could provide a significant competitive advantage against existing injectable treatments, such as AbbVie's Humira, in a market with limited options. Traders will be closely watching for upcoming regulatory decisions.
At the time of this announcement, INCY was trading at $90.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18B. The 52-week trading range was $53.56 to $112.29. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.